Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
SSY Group ( (HK:2005) ) has issued an announcement.
SSY Group Limited has announced that its antibiotic, Morinidazole, has received registration approval from China’s National Medical Products Administration. This development allows the drug to be marketed as a bulk drug for treating appendicitis and pelvic inflammatory disease caused by anaerobic bacteria, potentially enhancing the company’s market position and offering new opportunities for growth.
The most recent analyst rating on (HK:2005) stock is a Buy with a HK$7.00 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.
More about SSY Group
SSY Group Limited operates in the pharmaceutical industry, focusing on the development and production of medical products. The company specializes in antibiotics and other pharmaceutical preparations, targeting markets that require effective treatment solutions for bacterial infections.
Average Trading Volume: 14,439,585
Technical Sentiment Signal: Sell
Current Market Cap: HK$9.09B
Learn more about 2005 stock on TipRanks’ Stock Analysis page.